Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease

J Blommer, T Pitcher, M Mustapic, E Eren, PJ Yao… - Brain, 2023 - academic.oup.com
Besides motor symptoms, many individuals with Parkinson's disease develop cognitive
impairment perhaps due to coexisting α-synuclein and Alzheimer's disease pathologies and …

Nigrostriatal tau pathology in parkinsonism and Parkinson's disease

Y Chu, WD Hirst, HJ Federoff, AS Harms, AJ Stoessl… - Brain, 2024 - academic.oup.com
While Parkinson's disease remains clinically defined by cardinal motor symptoms resulting
from nigrostriatal degeneration, it is now appreciated that the disease commonly consists of …

Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti …

A Sharma, DF Muresanu, R Patnaik, PK Menon… - Progress in Brain …, 2021 - Elsevier
Military personnel deployed in combat operations are highly prone to develop Parkinson's
disease (PD) in later lives. PD largely involves dopaminergic pathways with hallmarks of …

Plasma α‐synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease

J Ren, C Pan, Y Wang, C Xue, H Lin… - Journal of …, 2022 - Wiley Online Library
The use of a diagnostic panel comprising multiple biomarkers has the potential to accurately
diagnose Parkinson's disease (PD). However, a panel consisting solely of plasma …

Protein modification in neurodegenerative diseases

S Ramazi, M Dadzadi, M Darvazi, N Seddigh… - MedComm, 2024 - Wiley Online Library
Posttranslational modifications play a crucial role in governing cellular functions and protein
behavior. Researchers have implicated dysregulated posttranslational modifications in …

Expression of tau and phosphorylated tau in the brain of normal and hemiparkinsonian rhesus macaques

JC Gambardella, W Schoephoerster… - Journal of …, 2023 - Wiley Online Library
Tau is a neuronal protein involved in microtubule stabilization and intracellular vesicle
transport in axons. In neurodegenerative disorders termed “tauopathies,” like Alzheimer's …

[HTML][HTML] Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson's disease

C Guo, T Wang, H Huang, X Wang, Y Jiang, J Li - Scientific Reports, 2024 - nature.com
Parkinson's disease (PD) is the second most frequently diagnosed neurodegenerative
disease, and it is characterized by the intracellular and extracellular accumulation of α …

The Golgi complex of dopaminergic enteric neurons is fragmented in a hemiparkinsonian rat model

M Cara‐Esteban, MP Marín… - Microscopy …, 2024 - Wiley Online Library
Since gastrointestinal disorders are early consequences of Parkinson's disease (PD), this
disease is clearly not restricted to the central nervous system (CNS), but also significantly …

Slowing Parkinson's disease progression with vaccination and other immunotherapies

D Vijayakumar, J Jankovic - CNS drugs, 2022 - Springer
Parkinson's disease (PD) is the second most common neurodegenerative disorder. There
are several recognized pathways leading up to dopaminergic neuron loss in the substantia …

The role of immune and inflammatory-related indicators in cognitive dysfunction and disease severity in patients with parkinson's disease

X Zhao, L Li, X Ma, Y Li, B Gao, W Luo - Journal of Neural Transmission, 2024 - Springer
We aimed to explore the role of immune and inflammatory indicators in cognitive dysfunction
and disease severity in patients with Parkinson's disease (PD). A total of 123 patients with …